Tudogyogyintezet Torokbalint
About Tudogyogyintezet Torokbalint
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
14
Janssen Research & Development, LLC
4
Pfizer
4
Amgen
3
Daiichi Sankyo, Inc.
3
Artu Biologicals
2
EMD Serono Research & Development Institute, Inc.
2
Vertex Pharmaceuticals Incorporated
2
Abbott
1
Agennix
1
Apollomics Inc.
1
Clinical Trials at Tudogyogyintezet Torokbalint
During the past decade, Tudogyogyintezet Torokbalint conducted 38 clinical trials. In the 10-year time frame, 38 clinical trials started and 15 clinical trials were completed, i.e. on
average, 39.5% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 7 clinical trials were completed. i.e. 43.8%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Efficacy and Safety of Grass Pollen Sublingual Immunotherapy
2006-12-01
2008-03-01
Completed
605
Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer
2008-11-01
2012-08-01
Completed
742
Long-term Efficacy and Safety Study With Oralgen Grass Pollen
2007-08-01
2009-01-01
Completed
356
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
2010-01-01
2015-12-01
Completed
1,069
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
2009-09-01
2016-01-01
Completed
347
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
2012-04-01
2016-07-01
Terminated
222
Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
2012-01-20
2016-03-30
Completed
501
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
2011-11-01
2015-06-27
Completed
135
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Tudogyogyintezet Torokbalint" #1 sponsor was "Hoffmann-La Roche" with 14 trials, followed by "Janssen Research & Development, LLC" with 4 trials
sponsored, "Pfizer" with 4 trials sponsored, "Amgen" with 3 trials sponsored and "Daiichi Sankyo, Inc."
with 3 trials sponsored. Other sponsors include 17 different institutions and
companies that sponsored additional 24 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Tudogyogyintezet Torokbalint"
#1 collaborator was "AstraZeneca" with 3 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Analytical Biochemical Laboratory" with 1 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were
collaborators in the rest 12 trials.
Clinical Trials Conditions at Tudogyogyintezet Torokbalint
According to Clinical.Site data, the most researched conditions in "Tudogyogyintezet Torokbalint" are
"Non-Small Cell Lung Cancer" (9 trials), "Carcinoma, Non-Small-Cell Lung" (6 trials), "Small Cell Lung Cancer" (4 trials), "Idiopathic Pulmonary Fibrosis" (3 trials) and "Non-small Cell Lung Cancer" (3 trials). Many other conditions were trialed in "Tudogyogyintezet Torokbalint" in a lesser frequency.
Clinical Trials Intervention Types at Tudogyogyintezet Torokbalint
Most popular intervention types in "Tudogyogyintezet Torokbalint" are "Drug" (49 trials), "Biological" (4 trials) and "Other" (4 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (12 trials), "Atezolizumab" (9 trials), "Carboplatin" (9 trials), "Docetaxel" (7 trials) and "Pemetrexed" (5 trials). Other intervention names were less common.
Clinical Trials Genders at Tudogyogyintezet Torokbalint
The vast majority of trials in "Tudogyogyintezet Torokbalint" are
50 trials for "All" genders.
Clinical Trials Status at Tudogyogyintezet Torokbalint
Currently, there are NaN active trials in "Tudogyogyintezet Torokbalint".
undefined are not yet recruiting,
8 are recruiting,
16 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 20 completed trials in Tudogyogyintezet Torokbalint,
undefined suspended trials,
and 6 terminated clinical trials to date.
Out of the total trials that were conducted in Tudogyogyintezet Torokbalint, 2 "Phase 1"
clinical trials were conducted, 12 "Phase 2" clinical
trials and 39 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 0 trials that are defined as “Not Applicable".